LOGIN  |  REGISTER
Viking Therapeutics

Biofrontera to Present at the 35th Annual ROTH Conference on March 13, 2023

March 02, 2023 | Last Trade: US$1.18 0.07 6.31

WOBURN, MA / ACCESSWIRE / March 2, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products will be presenting at the 35th Annual ROTH Conference in Laguna Nigel, CA being held March 12-14, 2023. Biofrontera, Inc. Chief Executive Officer, Erica Monaco, and Chief Financial Officer, Fred Leffler will represent the company at the conference.

The company presentation will be on March 13, 2023 at 8:00 AM PT and the webcast can be viewed here https://wsw.com/webcast/roth46/b8f.de/1934305. An archive of this webcast will also be available soon after the live presentation. Management will be available for 1x1 meetings during the conference. Please contact your ROTH MKM representative to schedule a meeting.

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Contacts:

Biofrontera Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page